Literature DB >> 30034591

Novel Aminoquinoline Derivatives Significantly Reduce Parasite Load in Leishmania infantum Infected Mice.

Jelena Konstantinović1, Milica Videnović2, Stefania Orsini3, Katarina Bogojević1, Sarah D'Alessandro4, Diletta Scaccabarozzi5, Nataša Terzić Jovanović6, Luigi Gradoni3, Nicoletta Basilico1, Bogdan A Šolaja1,7.   

Abstract

In this Letter, a detailed analysis of 30 4-aminoquinoline-based compounds with regard to their potential as antileishmanial drugs has been carried out. Ten compounds demonstrated IC50 < 1 μM against promastigote stages of L. infantum and L. tropica, and five compounds showed IC50 < 1 μM against intramacrophage L. infantum amastigotes. Two compounds showed dose-dependent enhancement of NO and ROS production by bone marrow-derived macrophages and remarkable reduction of parasite load in vivo, with advantage of being short-term and orally active. To the best of our knowledge, this is the first example of 4-amino-7-chloroquinoline derivatives active in Leishmania infantum infected mice.

Entities:  

Year:  2018        PMID: 30034591      PMCID: PMC6047044          DOI: 10.1021/acsmedchemlett.8b00053

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  18 in total

1.  Human serum albumin binding of certain antimalarials.

Authors:  Olivera S Marković; Ilija N Cvijetić; Mario V Zlatović; Igor M Opsenica; Jelena M Konstantinović; Nataša V Terzić Jovanović; Bogdan A Šolaja; Tatjana Ž Verbić
Journal:  Spectrochim Acta A Mol Biomol Spectrosc       Date:  2017-11-09       Impact factor: 4.098

2.  4-Aminoquinoline Derivatives as Potential Antileishmanial Agents.

Authors:  Luciana M R Antinarelli; Rafael M P Dias; Isabela O Souza; Wallace P Lima; Jacy Gameiro; Adilson D da Silva; Elaine S Coimbra
Journal:  Chem Biol Drug Des       Date:  2015-03-11       Impact factor: 2.817

3.  Synthesis of 4-aminoquinoline analogues and their platinum(II) complexes as new antileishmanial and antitubercular agents.

Authors:  Arturene M L Carmo; Flávia M C Silva; Patrícia A Machado; Ana P S Fontes; Fernando R Pavan; Clarice Q F Leite; Sergio R de A Leite; Elaine S Coimbra; Adilson D Da Silva
Journal:  Biomed Pharmacother       Date:  2011-05-04       Impact factor: 6.529

4.  Nitroimidazo-oxazole compound DNDI-VL-2098: an orally effective preclinical drug candidate for the treatment of visceral leishmaniasis.

Authors:  Suman Gupta; Vanessa Yardley; Preeti Vishwakarma; Rahul Shivahare; Bhawna Sharma; Delphine Launay; Denis Martin; Sunil K Puri
Journal:  J Antimicrob Chemother       Date:  2014-11-10       Impact factor: 5.790

5.  Antimalarial activity of 4-amidinoquinoline and 10-amidinobenzonaphthyridine derivatives.

Authors:  Vasiliy Korotchenko; Ramadas Sathunuru; Lucia Gerena; Diana Caridha; Qigui Li; Mara Kreishman-Deitrick; Philip L Smith; Ai J Lin
Journal:  J Med Chem       Date:  2015-04-09       Impact factor: 7.446

Review 6.  Status of vaccine research and development of vaccines for leishmaniasis.

Authors:  Portia M Gillespie; Coreen M Beaumier; Ulrich Strych; Tara Hayward; Peter J Hotez; Maria Elena Bottazzi
Journal:  Vaccine       Date:  2016-03-11       Impact factor: 3.641

7.  In vivo and in vitro anti-leishmanial activities of 4-nitro-N-pyrimidin- and N-pyrazin-2-ylbenzenesulfonamides, and N2-(4-nitrophenyl)-N1-propylglycinamide.

Authors:  M Auxiliadora Dea-Ayuela; Encarna Castillo; Marta Gonzalez-Alvarez; Celeste Vega; Miriam Rolón; Francisco Bolás-Fernández; Joaquín Borrás; M Eugenia González-Rosende
Journal:  Bioorg Med Chem       Date:  2009-09-20       Impact factor: 3.641

8.  Increase of leishmanicidal and tubercular activities using steroids linked to aminoquinoline.

Authors:  Luciana Mr Antinarelli; Arturene Ml Carmo; Fernando R Pavan; Clarice Queico F Leite; Adilson D Da Silva; Elaine S Coimbra; Deepak B Salunke
Journal:  Org Med Chem Lett       Date:  2012-05-02

Review 9.  Sitamaquine as a putative antileishmanial drug candidate: from the mechanism of action to the risk of drug resistance.

Authors:  P M Loiseau; S Cojean; J Schrével
Journal:  Parasite       Date:  2011-05       Impact factor: 3.000

10.  Antimalarials with Benzothiophene Moieties as Aminoquinoline Partners.

Authors:  Jelena Konstantinović; Milica Videnović; Jelena Srbljanović; Olgica Djurković-Djaković; Katarina Bogojević; Richard Sciotti; Bogdan Šolaja
Journal:  Molecules       Date:  2017-02-24       Impact factor: 4.411

View more
  2 in total

1.  Nongenotoxic 3-Nitroimidazo[1,2-a]pyridines Are NTR1 Substrates That Display Potent in Vitro Antileishmanial Activity.

Authors:  Cyril Fersing; Louise Basmaciyan; Clotilde Boudot; Julien Pedron; Sébastien Hutter; Anita Cohen; Caroline Castera-Ducros; Nicolas Primas; Michèle Laget; Magali Casanova; Sandra Bourgeade-Delmas; Mélanie Piednoel; Alix Sournia-Saquet; Valère Belle Mbou; Bertrand Courtioux; Élisa Boutet-Robinet; Marc Since; Rachel Milne; Susan Wyllie; Alan H Fairlamb; Alexis Valentin; Pascal Rathelot; Pierre Verhaeghe; Patrice Vanelle; Nadine Azas
Journal:  ACS Med Chem Lett       Date:  2018-12-19       Impact factor: 4.345

2.  4-Aminoquinoline-Based Adamantanes as Potential Anticholinesterase Agents in Symptomatic Treatment of Alzheimer's Disease.

Authors:  Katarina Komatović; Ana Matošević; Nataša Terzić-Jovanović; Suzana Žunec; Sandra Šegan; Mario Zlatović; Nikola Maraković; Anita Bosak; Dejan M Opsenica
Journal:  Pharmaceutics       Date:  2022-06-20       Impact factor: 6.525

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.